Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Many patients with ER-positive or PR-positive breast cancer are treated with endocrine
therapy. Although most ER/PR-positive tumors initially respond to hormonal therapy, patients
often experience disease progression. Everolimus, in combination with exemestane, has shown
activity in endocrine-resistant disease. This study will evaluate the efficacy of Everolimus+
anti-estrogen therapy in patients with ER-positive metastatic breast cancer who have
progressed after receiving anti-estrogen therapy.